Manipal Hospitals Kolkata unveils Manipal Comprehensive Cancer Care Centre and the advanced Bone Marrow Transplant unit on World Cancer Day

IMT News Desk
IMT News Desk
· 3 min read

Manipal Hospitals Kolkata strengthened its oncology capabilities with the launch of the Manipal Comprehensive Cancer Care Centre, with an advanced Clinical Haematology, Haemato-Oncology & Bone Marrow Transplant (BMT) Unit. The hospital also launched KAWACH- Community Health Screening Programme, an initiative of the Manipal Foundation in collaboration with the Kolkata Municipal Corporation (KMC).

The launch of the Comprehensive Cancer Care Centre addresses a critical gap in Eastern India’s oncology landscape, where rising cancer incidence is often compounded by late-stage diagnosis and limited access to integrated cancer services. According to data from the Indian Council of Medical Research (ICMR) and regional cancer registries, Eastern India, including West Bengal, Odisha, Bihar and the North-East, accounts for a substantial share of India’s cancer burden, with high prevalence of head and neck, gastrointestinal, breast and haematological cancers.

Nearly 60% of cancer cases in the region are diagnosed at advanced stages, leading to poorer outcomes and increased treatment complexity. The Centre is designed to deliver end-to-end cancer care under one roof, encompassing prevention, screening, early diagnosis, medical and surgical oncology, radiation oncology, haematology, bone marrow transplantation, supportive care and survivorship services through a coordinated multidisciplinary model.

Haemato-oncological conditions such as leukaemia, lymphoma and multiple myeloma contribute nearly 7-8% of India’s total cancer burden, with over 100,000 new blood cancer cases diagnosed annually, as per ICMR estimates. Bone Marrow Transplantation (BMT) remains a potentially curative therapy for several of these conditions; however, access remains limited, particularly outside major metropolitan centres. Data from the Indian Society of Blood and Marrow Transplantation (ISBMT) indicates that while India has completed over 25,000 stem cell transplants to date, fewer than 3,000 transplants are performed annually, far below actual demand. In this context, the BMT unit at Manipal Hospitals Kolkata, headed by Prof. (Dr.) Rajib De, Head- Clinical Haematology, Haemato-Oncology & Bone Marrow Transplant, Manipal Hospital EM Bypass, significantly enhances access to specialised, life-saving care for patients across Eastern India.

Dr. Sourav Datta, Director- Manipal Comprehensive Cancer Care (Mukundapur, Salt Lake & Siliguri Clusters), said, “The launch of the Manipal Comprehensive Cancer Care Centre marks a pivotal milestone in strengthening the oncology care ecosystem across Eastern India through its experienced and dedicated team of oncologists. By bringing together prevention, awareness, early detection, advanced diagnostics, medical and surgical oncology, radiation therapy, haematology and bone marrow transplantation within a coordinated, multidisciplinary framework, we are addressing the full continuum of cancer care under one roof. The availability of advanced treatments such as bone marrow transplantation, offering long-term survival rates of nearly 60-80% in appropriately selected patients with haematological cancers, significantly enhances access to potentially curative therapies closer to home. This integrated, patient-centric approach not only improves clinical outcomes but also reduces the physical, emotional and financial burden on patients and their families, while ensuring continuity of care from diagnosis through treatment and survivorship.”

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk